thailand
Statement of Thailand to EB 126 (Jan 2010) on public health, innovation and intellectual property
Submitted by thiru on 21. January 2010 - 23:17The following statement was delivered by Thailand on Tuesday, 19 January 2010 during the discussion of agenda item 4.3 on public health, innovation and intellectual property. This statement requested Dr. Chan (Director-General, WHO) to conduct an investigation of the leaks of documents of the WHO Expert Working Group on R&D Financing to the IFPMA. In its statement, Thailand noted that the circle of trust had been broken.
I thank Madame DG to her explanation about the process and documentations including her constructive advices
PhRMA Special 301 submission on Thailand
Submitted by James Love on 12. March 2009 - 16:11The following discusses the 2009 PhRMA submission for the USTR Special 301 list on Thailand. Thailand is one of three Asian countries (China, Philippines and Thailand) that were singled out by PhRMA for the harshest treatment. The submission on Thailand covers several topics, including these:
KEI Letter to Thailand Prime Minister and Health Minister, regarding compulsory licensing decisions
Submitted by Staff on 4. March 2008 - 23:00Mr. Samak Sundaravej
Prime Minister
Government House
Nakornpratom Rd.
Dusit, Bangkok
Thailand 10300
His Excellency
Mr. Chaiya Sasomsap
Minister of Public Health
Tiwanont Rd.
Talad Kwan District
Nontaburi Province 11000
Thailand
March 4, 2008
Re: Thailand Compulsory Licenses and public health
Dear Prime Minister Sundaravej and Minister of Public Health Chaiya Sasomsap:
Thailand - Selected News Stories
Submitted by Staff on 5. July 2007 - 22:00September 5, 2007. David Cronin for Intellectual Property Watch. EU Split Over Thai Effort to Obtain Cheapter Patented Drugs.
July 24, 2007. Bangkok Post. Thai Activists Attack Drug Ban.
Thailand's Compulsory Licensing Controversy
Submitted by Staff on 19. June 2007 - 22:00Between November 2006 and January 2007, Thailand issued compulsory licenses for two AIDS drugs (efavirnz and the combination of lopinavir+ritonavir) and one antihypertension drug (clopidegrel). The pharmaceutical industry has vehemently objected to these compulsory licenses, and has sought the US government's assistance in the matter. Though USTR has been careful not to claim that the Thai government has violated the TRIPS Agreement, it did place Thailand on the 301 Report's Priority Watch List. Currently, the Thai government is in the process of deciding whe
KEI Statement on USTR 301 list reference to Thailand
Submitted by Staff on 29. April 2007 - 22:00Monday, 30 April 2007
"The sanctioning of countries for using legitimate and important flexibilities in the TRIPS agreement brings shame to all U.S. citizens who are increasingly seen in Thailand and elsewhere as bullies and hypocrites."